Biogen Idec. 현재 미국 증시에서 완전 HOT 이다.
바이오젠 아이덱 주가는 올 들어서만 28% 올랐다.
장중 한때 $480 (55만원)에 이르기도 했다. 왜일까?
수많은 다국적 제약업체도 번번히 고개를 떨구었던
알츠하이머 신약의 가능성 때문이다.
Aducanumab (BIIB037). brain내의 amyloid plaque의 감소 유발.
이는 정말 획기적인 관찰이다.
게다가 인지 기능이 떨어지는 속도도 늦추는 임상 결과다.
Phase II는 건너뛰고 바로 Phase III로 진행한다는 보도다.
과연 새로운 신세계가 열릴지...
Today Biogen Idec (NASDAQ:BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer’s disease (AD). These data are being presented today at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.
Treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain. Amyloid plaque is believed to play a key role in the development of the symptoms of AD. In exploratory analyses, a dose-dependent, statistically significant effect of slowing clinical decline was observed on the Mini Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scales.
“This is the first time an investigational drug for Alzheimer’s disease has demonstrated a statistically significant reduction on amyloid plaque as well as a statistically significant slowing of clinical impairment in patients with prodromal or mild disease,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen Idec. “Based on these results, we are advancing the aducanumab clinical program to Phase 3 with plans to initiate enrollment later this year.”